New device is designed to improve survival rates from heart attack in high-risk heart patients.
NEPTUNE, N.J., March 24, 2011 /PRNewswire-USNewswire/ -- Today at Jersey Shore University Medical Center, 66-year-old heart attack survivor Charles Theodora from Ocean Township became the first NY/NJ Metropolitan resident to be implanted with the experimental AngelMed Guardian cardiac monitor and alert system device that could alert him if a heart attack is imminent.
"The key to the AngelMed Guardian system is the ability to track significant changes in the heart's electrical signal and then alert the patient to seek medical attention immediately," says Charles Koo, M.D., cardiologist with Meridian CardioVascular Network and principal investigator at Jersey Shore University Medical Center. "If this system proves to be effective in early detection and warning of potentially life-threatening heart conditions, we may be able to shift the paradigm for early treatment at the onset of heart attacks."
After having a second heart attack this past February, Theodora underwent bypass surgery at Jersey Shore and knew that he was susceptible to another attack." I chose to participate in this trial because of the trust I have in Dr. Koo and Jersey Shore," says Theodora. "I truly believe that this device will buy me more time to get to the emergency room if I start to have heart attack symptoms."
Clinical trial research is a critical component in how Jersey Shore University Medical Center advances the diagnosis and treatment of its patients. This ALERTS Pivotal US trial for the AngelMed Guardian implantable cardiac monitor and alert system is one example of research underway by the team of Meridian CardioVascular Network specialists in a continuing effort to expand cardiovascular research throughout central New Jersey.
"Experimental and clinical studies have shown that most of the damage to the heart occurs two hours after coronary occlusion," says AngelMed's Chief Operating Officer Jonathan Harwood. "We've designed the device to warn patients of this and other cardiac events hours — perhaps even days — before they occur."
According to the American Heart Association, one in every five deaths in the United States is attributable to coronary heart disease. In addition, 50 percent of heart-attack fatalities occur within one hour of the onset of symptoms and before the patient even reaches the hospital.
The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker with a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals. The system tracks changes in the heart's electrical signal and then vibrates causing an accompanying pager to beep and a red light to flash. Patients are told to call their physician when the alert is triggered and go directly to the emergency room to increase their chance of survival.
To participate in the ALERTS study, patients must have had a heart attack or open heart surgery within the past six months and meet other specific criteria. For more information on the AngelMed Guardian system or the ALERTS study protocol, visit www.jerseyshoreuniversitymedicalcenter.com or contact Jersey Shore University Medical Center Research Services at 732-776-2953.
About Jersey Shore University Medical Center
Jersey Shore University Medical Center, a member of the Meridian Health family, is a not-for-profit teaching hospital and home to K. Hovnanian Children's Hospital – the first children's hospital in Monmouth and Ocean counties. Jersey Shore is the regional provider of cardiac surgery, a program which has been ranked among the best in the Northeast, and is home to the only trauma center and stroke rescue center in the region. Jersey Shore University Medical Center specializes in cardiovascular care, orthopedics and rehabilitation, cancer care, neuroscience, and women's specialty services.
CONTACT: Robert Cavanaugh, Public Relations Manager, +1-732-776-4166
SOURCE Jersey Shore University Medical Center